Holly L Peay1,2, Barbara B Biesecker3, Benjamin S Wilfond4, Jill Jarecki5, Kendall L Umstead3, Diana M Escolar6, Aad Tibben7. 1. 1 RTI International, Research Triangle Park, NC, USA. 2. 2 Parent Project Muscular Dystrophy, Hackensack, NJ, USA. 3. 3 Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. 4. 4 Seattle Children's Hospital, Seattle, WA, USA. 5. 5 Cure SMA, Elk Grove Village, IL, USA. 6. 6 Kennedy Krieger Institute, Baltimore, MD, USA. 7. 7 Leiden University Medical Center, Leiden, The Netherlands.
Abstract
BACKGROUND/AIMS: Pediatric rare disease presents a challenging situation of high unmet need and a limited pool of potential clinical trial participants. Understanding perspectives of parents of children who have not participated in trials may facilitate approaches to optimize participation rates. The objective of this study was to explore factors associated with parental interest in enrolling children with pediatric neuromuscular disorders in clinical trials. METHODS:Parents of individuals with Duchenne or Becker muscular dystrophy and spinal muscular atrophy were recruited through advocacy organizations, a registry, and clinics. These parents ( N = 203) completed a questionnaire including assessments of barriers and facilitators to clinical trial participation, parents' interest in trial participation, and their perceptions of others' views about participation in a clinical trial. RESULTS: Trial interest in participating parents was high (64% combined group). The most highly endorsed barrier to participation was the possibility of receiving placebo, followed by not having enough information on risks and trial procedures. Compared to parents of children with Duchenne or Becker muscular dystrophy, parents of children with spinal muscular atrophy endorsed significantly more information and knowledge barriers. The greatest facilitators of participation were (1) confidence in improving disease understanding and (2) guarantee to receive the treatment after a successful trial. A logistic regression model, χ2 (4, n = 188) = 80.64, p < .001, indicated that higher perceived barriers and more frequent trial communication by the provider were associated with lower interest, while positive trial perceptions by the child's providers and concordance in trial perceptions among those close to the decision-maker were associated with higher interest. CONCLUSION: We found high parental interest in pediatric neuromuscular trials that was tempered by concerns about the potential for randomization to a placebo arm. Participants perceived that their trial participation would be facilitated by additional education and guidance from their clinicians. Yet, intentions were negatively associated with frequency of provider communication, perhaps reflecting waning parental interest with a greater understanding of limitations in trial access, increased sophistication in their understanding of trial design, and appreciation of potential burden. To support parents' informed decisions, it is important to educate them to evaluate the quality of research, as well as providing lay information explaining the use of placebo, trial processes, and potential barriers to long-term drug access. Our findings should inform the development of targeted educational content, clinician training, and decision support tools.
RCT Entities:
BACKGROUND/AIMS: Pediatric rare disease presents a challenging situation of high unmet need and a limited pool of potential clinical trial participants. Understanding perspectives of parents of children who have not participated in trials may facilitate approaches to optimize participation rates. The objective of this study was to explore factors associated with parental interest in enrolling children with pediatric neuromuscular disorders in clinical trials. METHODS: Parents of individuals with Duchenne or Becker muscular dystrophy and spinal muscular atrophy were recruited through advocacy organizations, a registry, and clinics. These parents ( N = 203) completed a questionnaire including assessments of barriers and facilitators to clinical trial participation, parents' interest in trial participation, and their perceptions of others' views about participation in a clinical trial. RESULTS: Trial interest in participating parents was high (64% combined group). The most highly endorsed barrier to participation was the possibility of receiving placebo, followed by not having enough information on risks and trial procedures. Compared to parents of children with Duchenne or Becker muscular dystrophy, parents of children with spinal muscular atrophy endorsed significantly more information and knowledge barriers. The greatest facilitators of participation were (1) confidence in improving disease understanding and (2) guarantee to receive the treatment after a successful trial. A logistic regression model, χ2 (4, n = 188) = 80.64, p < .001, indicated that higher perceived barriers and more frequent trial communication by the provider were associated with lower interest, while positive trial perceptions by the child's providers and concordance in trial perceptions among those close to the decision-maker were associated with higher interest. CONCLUSION: We found high parental interest in pediatric neuromuscular trials that was tempered by concerns about the potential for randomization to a placebo arm. Participants perceived that their trial participation would be facilitated by additional education and guidance from their clinicians. Yet, intentions were negatively associated with frequency of provider communication, perhaps reflecting waning parental interest with a greater understanding of limitations in trial access, increased sophistication in their understanding of trial design, and appreciation of potential burden. To support parents' informed decisions, it is important to educate them to evaluate the quality of research, as well as providing lay information explaining the use of placebo, trial processes, and potential barriers to long-term drug access. Our findings should inform the development of targeted educational content, clinician training, and decision support tools.
Authors: Sangeeta Mehta; Friederike Quittnat Pelletier; Maedean Brown; Cheryl Ethier; David Wells; Lisa Burry; Rod MacDonald Journal: Intensive Care Med Date: 2011-11-26 Impact factor: 17.440
Authors: Alejandro Hoberman; Nader Shaikh; Sonika Bhatnagar; Mary Ann Haralam; Diana H Kearney; D Kathleen Colborn; Michelle L Kienholz; Li Wang; Clareann H Bunker; Ron Keren; Myra A Carpenter; Saul P Greenfield; Hans G Pohl; Ranjiv Mathews; Marva Moxey-Mims; Russell W Chesney Journal: JAMA Pediatr Date: 2013-06 Impact factor: 16.193
Authors: Daniela L Buscariollo; Mario A Davidson; Margo Black; William E Russell; Russell L Rothman; Daniel J Moore Journal: PLoS One Date: 2012-08-28 Impact factor: 3.240
Authors: Rebecca R Moultrie; Megan A Lewis; Ryan S Paquin; Ann Lucas; Jill Jarecki; Holly L Peay Journal: J Genet Couns Date: 2017-12-20 Impact factor: 2.537
Authors: Holly Landrum Peay; Ryan Fischer; Janice P Tzeng; Sharon E Hesterlee; Carl Morris; Amy Strong Martin; Colin Rensch; Edward Smith; Valeria Ricotti; Katherine Beaverson; Hannah Wand; Carol Mansfield Journal: PLoS One Date: 2019-05-01 Impact factor: 3.240
Authors: Ryan S Paquin; Ryan Fischer; Carol Mansfield; Brennan Mange; Katherine Beaverson; Annie Ganot; Amy Strong Martin; Carl Morris; Colin Rensch; Valeria Ricotti; Leo J Russo; Alesia Sadosky; Edward C Smith; Holly L Peay Journal: Orphanet J Rare Dis Date: 2019-05-09 Impact factor: 4.123
Authors: Katherine D Mathews; Kristin M Conway; Amber M Gedlinske; Nicholas Johnson; Natalie Street; Russell J Butterfield; Man Hung; Emma Ciafaloni; Paul A Romitti Journal: Children (Basel) Date: 2021-09-23
Authors: Andrew R Wong; Virginia Sun; Kevin George; Jennifer Liu; Simran Padam; Brandon A Chen; Thomas George; Arya Amini; Daneng Li; Mina S Sedrak Journal: JCO Oncol Pract Date: 2020-04-02
Authors: Laurie S Conklin; Peter A Merkel; Lauren M Pachman; Hemang Parikh; Shefa Tawalbeh; Jesse M Damsker; David D Cuthbertson; Gabrielle A Morgan; Paul A Monach; Yetrib Hathout; Kanneboyina Nagaraju; John van den Anker; Carol A McAlear; Eric P Hoffman Journal: Steroids Date: 2018-10-21 Impact factor: 2.668
Authors: Karin J Naarding; Nathalie Doorenweerd; Zaïda Koeks; Ruben G F Hendriksen; Kinita A Chotkan; Yvonne D Krom; Imelda J M de Groot; Chiara S Straathof; Erik H Niks; Hermien E Kan Journal: J Neuromuscul Dis Date: 2020